These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 18791800)
1. Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. Saisho Y; Harris PE; Butler AE; Galasso R; Gurlo T; Rizza RA; Butler PC J Mol Histol; 2008 Oct; 39(5):543-51. PubMed ID: 18791800 [TBL] [Abstract][Full Text] [Related]
2. Vesicular monoamine transporter, type 2 (VMAT2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas. Freeby M; Ichise M; Harris PE Islets; 2012; 4(6):393-7. PubMed ID: 23221614 [TBL] [Abstract][Full Text] [Related]
3. Species-specific vesicular monoamine transporter 2 (VMAT2) expression in mammalian pancreatic beta cells: implications for optimising radioligand-based human beta cell mass (BCM) imaging in animal models. Schäfer MK; Hartwig NR; Kalmbach N; Klietz M; Anlauf M; Eiden LE; Weihe E Diabetologia; 2013 May; 56(5):1047-56. PubMed ID: 23404442 [TBL] [Abstract][Full Text] [Related]
4. Cross-sectional and Test-Retest Characterization of PET with [(18)F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes. Freeby MJ; Kringas P; Goland RS; Leibel RL; Maffei A; Divgi C; Ichise M; Harris PE Mol Imaging Biol; 2016 Apr; 18(2):292-301. PubMed ID: 26370678 [TBL] [Abstract][Full Text] [Related]
5. Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging. Cline GW; Naganawa M; Chen L; Chidsey K; Carvajal-Gonzalez S; Pawlak S; Rossulek M; Zhang Y; Bini J; McCarthy TJ; Carson RE; Calle RA Diabetologia; 2018 Dec; 61(12):2598-2607. PubMed ID: 29721633 [TBL] [Abstract][Full Text] [Related]
6. VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease. Freeby M; Goland R; Ichise M; Maffei A; Leibel R; Harris P Diabetes Obes Metab; 2008 Nov; 10 Suppl 4():98-108. PubMed ID: 18834437 [TBL] [Abstract][Full Text] [Related]
7. New perspectives of vesicular monoamine transporter 2 chemical characteristics in mammals and its constant expression in type 1 diabetes rat models. Hong F; Liu L; Fan RF; Chen Y; Chen H; Zheng RP; Zhang Y; Gao Y; Zhu JX Transl Res; 2014 Feb; 163(2):171-82. PubMed ID: 24161354 [TBL] [Abstract][Full Text] [Related]
8. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. Goland R; Freeby M; Parsey R; Saisho Y; Kumar D; Simpson N; Hirsch J; Prince M; Maffei A; Mann JJ; Butler PC; Van Heertum R; Leibel RL; Ichise M; Harris PE J Nucl Med; 2009 Mar; 50(3):382-9. PubMed ID: 19223416 [TBL] [Abstract][Full Text] [Related]
9. VMAT2 gene expression and function as it applies to imaging beta-cell mass. Harris PE; Ferrara C; Barba P; Polito T; Freeby M; Maffei A J Mol Med (Berl); 2008 Jan; 86(1):5-16. PubMed ID: 17665159 [TBL] [Abstract][Full Text] [Related]
10. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. Anlauf M; Eissele R; Schäfer MK; Eiden LE; Arnold R; Pauser U; Klöppel G; Weihe E J Histochem Cytochem; 2003 Aug; 51(8):1027-40. PubMed ID: 12871984 [TBL] [Abstract][Full Text] [Related]
12. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. Kung MP; Hou C; Lieberman BP; Oya S; Ponde DE; Blankemeyer E; Skovronsky D; Kilbourn MR; Kung HF J Nucl Med; 2008 Jul; 49(7):1171-6. PubMed ID: 18552132 [TBL] [Abstract][Full Text] [Related]
13. In vivo imaging of vesicular monoamine transporter 2 in pancreas using an (18)F epoxide derivative of tetrabenazine. Kung HF; Lieberman BP; Zhuang ZP; Oya S; Kung MP; Choi SR; Poessl K; Blankemeyer E; Hou C; Skovronsky D; Kilbourn M Nucl Med Biol; 2008 Nov; 35(8):825-37. PubMed ID: 19026944 [TBL] [Abstract][Full Text] [Related]
14. Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats. Tsao HH; Lin KJ; Juang JH; Skovronsky DM; Yen TC; Wey SP; Kung MP Nucl Med Biol; 2010 May; 37(4):413-9. PubMed ID: 20447551 [TBL] [Abstract][Full Text] [Related]
15. A shared comparison of diabetes mellitus and neurodegenerative disorders. Morsi M; Maher A; Aboelmagd O; Johar D; Bernstein L J Cell Biochem; 2018 Feb; 119(2):1249-1256. PubMed ID: 28681964 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [ Naganawa M; Lim K; Nabulsi NB; Lin SF; Labaree D; Ropchan J; Herold KC; Huang Y; Harris P; Ichise M; Cline GW; Carson RE Mol Imaging Biol; 2018 Oct; 20(5):835-845. PubMed ID: 29468404 [TBL] [Abstract][Full Text] [Related]
17. A novel optical tracer for VMAT2 applied to live cell measurements of vesicle maturation in cultured human β-cells. Pecic S; Milosavic N; Rayat G; Maffei A; Harris PE Sci Rep; 2019 Apr; 9(1):5403. PubMed ID: 30932004 [TBL] [Abstract][Full Text] [Related]
18. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. Souza F; Simpson N; Raffo A; Saxena C; Maffei A; Hardy M; Kilbourn M; Goland R; Leibel R; Mann JJ; Van Heertum R; Harris PE J Clin Invest; 2006 Jun; 116(6):1506-13. PubMed ID: 16710474 [TBL] [Abstract][Full Text] [Related]
19. Decreased striatal vesicular monoamine transporter 2 (VMAT2) expression in a type 1 diabetic rat model: A longitudinal study using micro-PET/CT. Jiang D; Kong Y; Ren S; Cai H; Zhang Z; Huang Z; Peng F; Hua F; Guan Y; Xie F Nucl Med Biol; 2020; 82-83():89-95. PubMed ID: 32120243 [TBL] [Abstract][Full Text] [Related]
20. Imaging of beta-cell mass and function. Ichise M; Harris PE J Nucl Med; 2010 Jul; 51(7):1001-4. PubMed ID: 20554742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]